Clipping of news on Brazilian Culture, Law and Citizenship
29/10/2012
This article was translated by an automatic translation system, and was therefore not reviewed by people.
Lab German patent holder of pramipexole and Fiocruz had signed agreement for technology transfer
The National Health Surveillance Agency (ANVISA) released this week the record for the Institute of Drug Technology (Farmanguinhos), the Oswaldo Cruz Foundation (Fiocruz), can start producing the drug Pramipexole, used for the treatment of Parkinson's .
The initiative is part of the Productive Development Policy (PDP) of the federal government, which aims to strengthen the Brazilian pharmaceutical chemistry industry. In November last year, the German laboratory Boehringer Ingelheim, the drug's patent holder, and Farmanguinhos signed agreement that initiated the transfer of technology to developing and manufacturing the product.
According to the deputy director of Institutional Management Farmanguinhos, Jorge Mendonca, the agreement provides for a maximum term of five years to complete the transfer of technology within the domestic industry. In the first three years, the remedy will be bought by German industry, but will have the mark of Farmanguinhos. In the last two years of the contract, 50% of production will be acquired and another 50% will be produced in the unit.
"We intend to benefit the population in two lines: indirectly, by increasing the technological capacity of the country and absorbing new technologies for production of medicines. Else, is a more direct way, ensuring people's access to a cutting edge product, providing greater comfort , mainly grip and better quality of life for people suffering from Parkinson's disease, "said Mendonca.
The deputy director said that the population will begin to benefit from the initiative from December this year or January next year. He said besides the nationalization of medicine, the initiative influences the reduction of cost of purchasing the product. As of now, the expectation is that there is a reduction of at least 20%, and at the end of the process, the reduction is around 30%.
According to Fiocruz currently drugs to treat the disease are subsidized by the Ministry of Health through financial transfers. Last year, we invested approximately R$ 37 million to states to meet the demand for pramipexole.
Parkinson's disease is a degenerative disorder of the central nervous system and one of the most common neurological problems today. According to Fiocruz, it is estimated that there are 100 to 200 cases per 100 thousand. Data from the World Health Organisation (WHO) show that 1% of the population over age 65 suffers from the disease, which usually arises from the age of 50. In Brazil, it is estimated that at least 200 000 people have Parkinson's.
Source: Everyday Health
Our news are removed entirely from the sites of our partners. For this reason, we can not change their content even in cases of typos.
This article was translated by an automatic translation system, and was therefore not reviewed by people.